Hadassah Medical Center-ko ikertzaileekin lankidetzan egindako argitalpenak (39)

2024

  1. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients

    The Lancet Infectious Diseases, Vol. 24, Núm. 1, pp. e59-e68

  2. Dynamic Coronary Roadmap versus standard angiography for percutaneous coronary intervention: the randomised, multicentre DCR4Contrast trial

    EuroIntervention, Vol. 20, Núm. 3, pp. e198-e206

2023

  1. Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel

    Journal of Medical Genetics, Vol. 60, Núm. 12, pp. 1186-1197

  2. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

    The Lancet, Vol. 401, Núm. 10373, pp. 269-280

  3. Rationale and design of the Dynamic Coronary Roadmap for Contrast Reduction (DCR4Contrast) in PCI randomized controlled trial

    American Heart Journal, Vol. 263, pp. 151-158

2022

  1. Corrigendum to ‘Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study’ [European Journal of Cancer 154 (2021) 246-252] (European Journal of Cancer (2021) 154(246-252) (S0959804921004044), (10.1016/j.ejca.2021.06.029))

    European Journal of Cancer

  2. Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021

    Transplant Infectious Disease, Vol. 24, Núm. 6

  3. ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors

    Journal of Neuroendocrinology, Vol. 34, Núm. 3

  4. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients with Cancer: A Narrative Review

    JAMA Oncology, Vol. 8, Núm. 12, pp. 1830-1839

  5. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 28, Núm. 9, pp. 1424-1456

2021

  1. Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study

    European Journal of Cancer, Vol. 154, pp. 246-252

  2. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

    Annals of Oncology, Vol. 32, Núm. 10, pp. 1245-1255

2020

  1. Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction—Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial

    American Heart Journal, Vol. 224, pp. 129-137

2019

  1. An international perspective on hospitalized patients with viral community-acquired pneumonia

    European Journal of Internal Medicine, Vol. 60, pp. 54-70

  2. International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia

    Journal of Infection, Vol. 79, Núm. 4, pp. 300-311

  3. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

    Annals of Oncology, Vol. 30, Núm. 5, pp. 766-773

2018

  1. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis

    British Journal of Haematology

  2. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals

    Clinical Microbiology and Infection, Vol. 24, Núm. 10, pp. 1070-1076

  3. Microbiological testing of adults hospitalised with community-acquired pneumonia: An international study

    ERJ Open Research, Vol. 4, Núm. 4

  4. Telotristat ethyl in carcinoid syndrome: Safety and efficacy in the TELECAST phase 3 trial

    Endocrine-Related Cancer, Vol. 25, Núm. 3, pp. 309-322